With increasing numbers of countries implementing the use of the rotavirus vaccine, rotavirus and acute gastroenteritis hospitalizations and mortalities continue to show a sustained reduction.
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
No significant decrease seen in incidence rates of tetanus, diphtheria with routine vaccination of adults.
The overall vaccine effectiveness against any influenza virus associated with medically attended ARI is 45% for the current season.
Updated recommendations for the use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine have been developed by the Advisory Committee on Immunization Practices (ACIP).
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the child and adolescent immunization schedule for ages 18 years and younger in the United States.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the adult immunization schedule for ages 19 years and older in the United States.
In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.
